MEDIUM conviction · 207 dossiers

Five straight up sessions took HPE to a $53.22 close on 2026-08-07 with the 2026-08-04 gap floor at $50.24 still untested; Trefis put the five-day move at +19.8% against +5.6% for the S&P 500, so this leg is no longer pure sector beta.…

Post-print floor held: the 2026-08-05 undercut to $353.69 closed green on CVS's Aetna guide raise, and 2026-08-07 closed $385.00 (+4.84%), back above the 50-day of $374.23 and the highest close since 07-28. Morgan Stanley's 08-05 upgrade…

Defense-electronics turnaround still re-rating on record bookings and a promised FCF turn, but the stock has given back ~20% from its $128.45 ATH and now chops near the analyst median (~$103) into a binary ~Aug 10-18 Q4/full-year print.…

The 2026-08-03 divergence extended: MU closed $892.67 on 2026-08-04, +21.8% over four sessions, and Counterpoint put Q2 DRAM share at Micron 25% versus SK Hynix 26%. Price remains under a falling 50-day near $958 with no confirmed base;…

Identity-security re-rating in its second, sell-side-led leg; the upgrade wave is still building nearly two months post-print — Wells Fargo lifted its target to $150 from $100 on 2026-07-20, collapsing the low-end dispersion. Cyber theme…

Freight-cycle recovery intact; sell-side has fully caught up into a $20–35 battleground — bears $20 (Goldman 07-16, Susquehanna 07-14), bulls $30–35 (BMO $35 initiation 07-14, Stifel/Truist/Citi $30). Narrative matured from mispriced to…

Controller-mix decoupling got its first hard datapoint on 2026-08-06 — SIMO +8.42% to $267.43 while Western Digital fell 16% and SanDisk 11% on beat-but-guide-light prints — then gave most of it back on 08-07 (-4.23% to $256.12, $18.87 off…

Q2 on 2026-08-04 cleared every self-set number — revenue $229.3M (+41%), marketplace +45%, Adj EBITDA $14.1M — and the new CEO raised FY2026 growth to 33–34% from 27–28%. Price took three sessions to agree, closing $93.15 on 08-07 back…

Three higher lows since the 2026-07-29 China-substitution break, and the domestic SSA800 now benchmarks as a 2008-generation ASML tool — but the 2026-08-04 close of $1,711.89 is still under a 20-day of $1,727.29 and a 50-day of $1,755.37,…

Custom-silicon and AI-networking royalty funded by the VMware software annuity. 2026-08-04's +6.61% to $418.16 reclaimed the 50-day, but the catalyst was Palantir's print and a record S&P close, not Broadcom news. The genuinely new item is…

InP scarcity went sector-wide on 2026-08-06 (TrendForce, quoting Lumentum's CEO on a >30% supply gap "worse than memory"), and AXTI ran $68.61 to $88.58 into 2026-08-07 (+17.84% on 19.0M shares), reclaiming the 50-day at $72.41. Lumentum…

US commercial re-acceleration to +149% YoY broke the 2026 de-rating: PLTR gapped +29.45% to $162.66 on 2026-08-04, reclaiming the $152.54 200-day and leaving $126.97–$143.28 unfilled. The fundamental case improved and the entry structure…

Both binaries cleared: the first-ever print beat on revenue and EPS (2026-08-04), then 911.5M shares unlocked 2026-08-06 without a wall — low $105.11, close $114.92 (+6.14%). What replaces them is $18.37B quarterly capex against ~$13.2B…

The 2026-08-04 beat was fully round-tripped by the 2026-08-05 close of $211.14; the repricing that stuck came 2026-08-07, when BofA initiated at Buy/$367 and shares closed $252.49 (+12.37%). A new covering firm plus a panel high moving…

AI-compute narrative re-accelerated on the 2026-07-23 analyst event — named multi-gigawatt Anthropic/OpenAI commitments, Helios rack-scale ramp, TAM lifted to $2T by 2030 — drawing a fresh upgrade cluster (Roth $650, Cantor $700, Futurum…

Titanium/superalloy aero-defense supplier digesting a June breakout above the reclaimed $183.30 ATH shelf: ~9% off the $204.09 high, RSI cooled to ~66, consensus PT $200.33 back above spot. Q2 lands 2026-08-06; peer CRS prints 2026-07-30…

GPU-neocloud narrative re-accelerated after NVIDIA disclosed a 9.3% stake (7/20) and PT raises followed (Northland $410, Baird initiates Outperform $250); Alphabet's 7/22 "demand outpaces capacity" answers the Meta-Compute bear case. The…

Liquid-cooling/datacenter-power bottleneck story intact but the revision cycle has stalled — RBC cut its target and the two newest sponsors (Baird $370, KeyBanc $360 on 07-23) initiated at the bottom of the range as the theme cooled to…

War-premium crude expression left for dead in early July has violently re-fired: the June-17 US–Iran MOU collapsed, nine nights of US airstrikes and a July-7 Hormuz tanker attack drove WTI crude +~20% to $83 (Jul 20). Unlike May, the…

Bitcoin-miner-to-HPC re-rate confirmed by Anthropic's 20-year ~$19B lease (2026-07-06); theme ACCELERATING and cluster-confirmed (Hut 8's $9.8B deal, 2026-07-20). A ~$3.5B financing overhang, the NY hyperscale moratorium aimed at Lake…

Post-deal de-rating unwinding: the 2026-07-16 Q2 beat (sales $12.593B, adj EPS $1.31 vs $1.28) plus the first FY26 guidance raise of the year to $5.45–$5.60, then FDA approval of Freenome's SimpleScreen CRC blood test on 2026-07-27, which…

Post-scandal behavioral-health turnaround re-rate now cluster-confirmed: UBS $39, Keybanc $40, Guggenheim $38, TD Cowen $36 all lifted above the old $30.20 high in 11 days, driving a breakout to ~$34.50. The 2026-07-28 Q2 print (Florida…

Special-situation breakup narrative accelerating: Reuters (2026-07-17) reports ACI exploring a ~$1.5B sale of its Biller unit, which would surface sum-of-the-parts value and re-rate the faster-growing Payments Software segment. Q1 beat +…

China WFE-localization plus a memory-capex rebound re-accelerated ACMR's order book (new orders +65% YoY at the 2026-05-07 Q1 print), carrying it to a $109.87 all-time high on 2026-06-18 behind Roth's $125 target. Six weeks on, the…

clonoSEQ MRD pure-play inflecting to self-funding growth (MRD rev +53% YoY, profitability turning); June 15 Immune Medicine separation adds a value-unlock leg. But the tape just broke to fresh 52-wk highs (~$22.92) above the $20–22…

Mitapivat SCD label-expansion re-rate: positive RISE UP Phase 3 (2026-06-15) plus FDA Priority Review (2026-07-07) set a 2026-11-01 PDUFA binary. The acceptance pop is digested and backup asset tebapivat's 2026-07-21 Phase 2 failure thins…

Allegiant closed the $1.5B Sun Country acquisition (2026-05-13) to become the largest US leisure airline just as fuel flipped to a tailwind and the whole sell-side re-rated it to $142–$160; the move has more than doubled off the low, and…

Class validation arrived without a bid: the FDA approved Takeda's ORZEYFUL (oveporexton) for NT1 on 2026-08-05, proving the OX2R mechanism commercially, yet ALKS closed 2026-08-07 at $49.17, 11.0% below its $55.22 high with RSI 39.3. Q2…

Record-orders inflection: Q2 2026 bookings $201.3M (+49% YoY), 1.31x book-to-bill, backlog $298.0M vs $236.6M a year earlier — the first clean order break after two flat revenue years. Narrative is ACCELERATING, but the entire re-rating…

Physical-AI pure-play narrative still accelerating (Rosenblatt top H2-2026 pick, PT $120; Zacks upgrade to #2 Buy 2026-07-21), but the post-Rosenblatt breakout to ~$80 round-tripped to ~$67.61 by 2026-07-24, forfeiting the $72 shelf on a…

Box-office recovery flipped from meme-squeeze dormancy to a fundamental earnings inflection: Q2 (2026-07-20) adj EPS $0.14 vs $(0.06) est, revenue $1.597B beat, plus a Wedbush $4 / Benchmark $3 upgrade cluster (2026-07-21). Narrative…

Wealth-platform operating leverage: Q2 2026 (2026-07-23) adjusted EPS $11.07 +22%, ROE 55%, record $1.81T AUM/AUA, at 11.18x forward. But organic flows decelerated to $3.1B from $4.2B in Q1, price sits ~15% above a flat ~$474…

Beat-and-raise on 2026-08-05 resolved the binary: ARR $410M +22% YoY, RPO +35%, FY revenue and margin guide both lifted, five PT raises inside 48 hours to a $12.5–$13 ceiling. Unfinished: net retention printed 103% (105% pro forma) against…

Generics-to-specialty re-rate keeps working — CREXONT EU approval, romidepsin exclusivity and the $1.1B Kashiv biosimilar build carried the stock to a fresh 52-week high at $18.39, and UBS's 2026-07-15 move to $23 finally opens sell-side…

Q2 landed bullish on 2026-07-29: sales $8.758B and adj EPS $1.35 both beat, orders $10.7B held book-to-bill at 1.23:1, and Q3 guidance came in above consensus on both lines. Four desks lifted targets to $197–215 on 07-30 and a 2-for-1…

Process-orchestration-for-AI-agents narrative re-rating a de-rated low-code name: Q2 on 2026-08-06 put cloud subscription revenue +23% YoY and lifted FY26 revenue guidance to $845–853M. Timing is the problem — RSI 70.2 after a 58%…

Profitability-inflection leg: the 2026-07-23 Q2 print took FY2026 adjusted EPS guidance from $0.00–$0.04 to $0.24–$0.32 against $0.06 consensus, on 77.2% gross margin and $153.6M revenue. But the revenue guide barely moved ($600–610M to…

Turnaround compounding into acceleration: third FY2026 guidance raise (rev $2.63-2.65B, EBITDA $338-342M) on the June 1 close of the $175.5M Family First deal, with price +55% off $6.24 in six weeks to $9.69 against a $10.32 high.…

Post-LOTUS de-risked anti–IL-1β (abdakibart) story: funded into 2029, Russell-included, sell-side $35–38, but digesting ~21% off the $24.27 high — MATURING, not accelerating. The 2026-07-30 Q2 call (Phase 3 design/BD tone, this week) is a…

The Aug 4 Q3 print flipped the operating line: organic revenue +9% after −3% in the March quarter, adjusted EBITDA margin 11.4% vs 5.4%, FY26 guide narrowed upward, and the $250M buyback finally activated (2.3M sh / $50.0M). The…

Cloud/AI re-rating leg: Cloud Intelligence external-customer revenue grew 40% YoY in the March-2026 quarter, Qwen3.8-Max shipped 2026-08-03 at $2/$6 per million tokens, and a 2026-08-07 report points to paid enterprise licensing. The…

Argentina country trade re-accelerated: June CPI printed 1.9% MoM on 2026-07-14 (first sub-2% of the cycle) and country risk broke to 402bp, tightest since April 2018, carrying BBAR to a fresh 52-week high of $22.47. Price now sits above…

Electric-aviation scale-up narrative re-accelerating: a $3.9B/991-unit backlog, the 2026-08-04 EXIM intent for up to $1B, and a July run of GE Aerospace, Loganair and FAA eIPP headlines have carried the stock +25.9% in three months into…

EMS arms-dealer to two secular ramps at once — AI datacenter liquid-cooling (AC&C +41% YoY, Q1 CY2026) and the 2026-06-15 Ouster Rev8 lidar scale-up (>100k units/yr, 10-yr life). Narrative accelerating, but the tape sits ~18% above the $78…

Self-help re-rate on a 12–13% grower: a 30% headcount cut plus a $1.0B buyback turned BILL GAAP-profitable and carried price from the 2026-06-22 low of $31.96 to $47.99 on 2026-08-07. The date moved — Q4/FY2026 lands 2026-08-19 after the…

Q2 print (2026-07-30) re-accelerated comps to +6.5% on +8.3% traffic from +2.4% in Q1 and lifted the FY comp guide to +3–4%; the Street repriced targets from a $38–50 band to $65–80 in one session. Turnaround narrative is accelerating…

Neocloud storage pick-and-shovel: the five-year ~$335M CoreWeave B2 Neo deal (2026-06-23) re-rated BLZE from the high-$7s to a 52-week high near $18, and sell-side is still chasing (Citizens to $16, 2026-07-23). Narrative accelerating but…

Legacy-pharma re-rating: the 2026-07-30 Q2 print beat on revenue ($12.973B vs $11.745B) and reset FY26 guidance entirely above the old range ($49.0–50.0B sales, $6.75–7.00 adj EPS). The AstraZeneca merger leg was denied by Reuters on…

June dormant-to-leader flip is confirming: the ~$7.52 breakout resolved up on the 2026-07-21 surge, Rosenblatt lifted its target to $13 (2026-07-16), and June ops printed 28.2M users / $800M net deposits. Theme accelerating; read is a…

M&A leg replaced the deleveraging leg on 2026-08-05: the board formed an independent committee after an unsolicited acquisition proposal, hiring Evercore, while Q2 revenue $153.2M missed the $155.64M consensus. Price marked a 52-week high…

Hormuz-shutdown VLGC rate shock converting into declared cash: Q1 (2026-06-02) printed $164M attributable, EPS $1.08 and a $0.67/sh dividend, with ~85% of Q2 days pre-fixed near $81,000/day vs Q1's $55,500. The 2026-08-28 half-year report…

Post-print re-rate: Q2 (2026-08-06) beat on revenue ($251.0M, +13%) and EPS ($0.66 vs $0.61) and cut guided FY26 margin compression to 0.5–1.5pp from 1.5–2.5pp, taking price to $38.98, 0.1% under the 52-week high. The leg being bought is a…

Cheap, high-margin insurtech SaaS put in play: a Morgan Stanley-run sale process plus a fresh Elliott activist stake. Shares popped ~13% to ~$6 on the 2026-07-09 Reuters report yet still sit below a plausible PE take-out. The trade is…

Q2 (2026-07-22) broke the value-trap frame: adjusted EPS $1.30 vs $0.63 consensus, 2,506 deliveries above the 2,200–2,400 guide, orders +3% YoY after Q1's -11.6%, FY delivery floor raised to 9,750. The leg being bought is entry-level share…

MolDX overhang lifted 2026-07-16, then the 2026-07-30 print converted policy into numbers: FY2026 revenue guide raised to $490–500M from $447–465M, adjusted EBITDA to $66–78M from $43–57M. What is being bought now is the estimate-revision…

Second FY26 guidance cut (2026-08-04: revenue $367–382M, adj EPS $0.31–0.36) was fully absorbed — the stock closed $8.20 on 08-07, above its $8.18 pre-print close, filling the gap in three sessions. The leg being bought is self-help: ~5%…

CD19 T-cell-engager-in-autoimmune narrative re-rated CGEM ~3x off the $5.68 low on CLN-978 lupus/RA single-dose remissions; now drifting to ~$17.10 in a bull flag under the $19.43 high with the big data catalyst spent and no dated readout…

Phase 3 CSU topline pulled forward to a September/October 2026 window at the 2026-08-06 Q2 print; the tape made a new 52-week high ($41.71, 2026-08-07) three weeks after a Phase 2 prurigo nodularis failure, with three Overweight target…

FCF-inflection thesis confirmed: Q2 (2026-07-23) delivered positive free cash flow and a sales beat, the stock gapped ~19%, and GLJ flipped to Buy ($15.6) — first above-spot target. The GOES-into-grid narrative is re-accelerating, but a…

Legacy specialty refiner re-rating into a DOE-funded SAF leader: Montana Renewables' MaxSAF 150 (150 MMgy, SAF volumes 4–5x prior) came online May 2026, the ~Jul 8 Gulfstream G800 supply win added a demand halo, and Feb-2026 45Z rules…

First full combined quarter post-Kito Crosby beat hard (adj EPS $0.61 vs $0.27 est) and drove a guidance raise on all three lines on 2026-07-30; the leg being bought is deleveraging from 4.9x toward sub-4x by FY28 on $70M of synergies. No…

Incumbent-exchange pivot into event contracts: the 2026-07-29 FutureSports index-futures deal plus record July ADV of 27M contracts (+23% YoY, reported 2026-08-04), against a stock still 16.9% below its 52-week high of $317.22. Operating…

Clinical binary already resolved (COMP006 positive 2026-07-07); the leg being bought now is regulatory — rolling NDA completion guided Q4 2026, H1 2027 launch, $433.3M cash into 2028. Q2 landed 2026-08-05 alongside a mixed shelf filing,…

Best fundamental print of the AI cycle (2026-07-30: rev $149M vs $144.08M cons.; Q3 guided $163–177M vs $146.33M) collided with a sector de-rate — the stock closed $52.88 on 2026-08-07, 28.5% under its $73.91 high and beneath the June…

Beat-and-raise on 2026-08-06 — record $210.8M quarter (+12.8% YoY) and FY26 guide lifted to $805–820M — has not re-rated a stock still 23.6% below its $221.74 52-week high. The leg is a toll on record M&A and litigation volume; the…

Interconnect/AEC royalty narrative still accelerating, not fading — new 52-week highs on late-June initiations (Evercore $325, Stifel $350, BofA $340) plus the early-July AI-buildout rally. But it's now mainstream and widely held, entering…

De-rated Dow laggard with a dated agentic-AI revenue proof point: the $1.6B three-year VA agentic ELA (2026-07-24) drove a 7% session on 2026-07-27 while the stock still trades near 13.8x the FY27 non-GAAP EPS guide. The 2026-08-26 Q2 FY27…

Agentic-AI security is now CRWD's own narrative, not a borrowed sector bid: the 2026-08-04 Threat Hunting Report and a second sell-side reset (BofA $230, Loop initiation $230) carried price to a record $214.42 close on 2026-08-07. Buying…

Utility T&D / grid-capex cycle with CTOS as the laggard specialty-rental picks-and-shovels name; the June breakout to $11.36 has stalled, retracing ~10% to retest the ~$10 shelf into a binary 2026-07-29 Q2 print. Theme now maturing and…

Q2 (2026-08-06) split the read: revenue $49.0M beat $48.21M and FY26 guide affirmed at $192–196M with adjusted EBITDA crossing to +$0.4M, but commercial CGT growth halved to +9% YoY from +26%. The narrative leg is now the profitability…

Geopolitical crude-supply shock (Iran ceasefire collapse 2026-07-08, Strait of Hormuz risk) is widening refined-product crack spreads and refiners lead the tape; sell-side target cluster raising into the move (TD Cowen $79→$98, Goldman…

Q2 2026 (2026-08-05) beat hard — adj EPS $5.48 vs $2.74 est, adj EBITDA ~$639M, EOP run-rate target raised to ≥$220M from ~$100M — yet the 2026-08-07 close of $58.46 sits 13.5% under the $67.62 high with RSI 37.6. Fundamentals improved,…

Single-banner turnaround re-rated on a Jul 6–8 sell-side upgrade cluster (JPM $170, UBS $145, Raymond James $140, Goldman off Sell to $125), pushing DLTR to $128.51 intraday Jul 15. Narrative is confirmed but no longer early, and the tape…

Complement re-rate has extended to a new 52-week high of $112.64; the 2026-08-04 Q2 print added a December MMN top-line and a new bifunctional candidate, and four broker PT raises in four sessions (08-03→08-06) are sell-side catch-up to a…

Head-and-neck re-acceleration: a 2026-06-23 first-ex-US glioblastoma treatment drove a +17.9% breakout to new 52-week highs (~$12.56 on 7/11), reclaiming the $11.99 Tolmar equity shelf. The 2026-07-21 AHNS podium with complete Alpha DaRT +…

Filing binary resolved: FDA accepted the z-rostudirsen exon-51 DMD BLA with Priority Review on 2026-07-20, PDUFA 2027-01-21 — Stock closed $26.25 on 2026-08-07 at its 52-week high with no dated catalyst for five months. MATURING: the…

Sell-side flipped from cutting to marking up in ten days — five PT raises 2026-07-10→07-17 (JPM $94, Canaccord $97, Citi $92, RJ $87, UBS $80) on the e.l.f. Hair launch and Rhode scaling, while the stock slipped to $72.25. Narrative…

June's sentiment re-rate rolled over; the 2026-08-04 beat-and-raise re-based the story on numbers — Q2 sales $883.2M vs $835.5M consensus, Q3 guide $905–935M vs $879.8M — and drew three target raises on 08-05 (UBS $215). At $152.08 the…

Q2 (2026-07-23) cleared the binary — revenue $929M +22%, adjusted EPS $4.31, NCOs 7.3%, FY guide lifted to +30–35% adjusted EPS growth — and price ran to $252.64, within 3.9% of the high. The credit-normalisation narrative still works, but…

Rare-disease specialty-pharma rollup went from single-broker to a coverage cluster — Canaccord initiated Buy/$60 on 2026-07-17, Craig-Hallum raised to $62 on 2026-07-28 — alongside +50.4% over three months and two pipeline headlines in…

The 2026-08-03 Q2 print resolved the plateau binary bullish: revenue $195.1M (+25% YoY) broke the three-quarter ~$190M band, adjusted EBITDA hit a record $30.1M, and Q3 was guided $198–208M above the $201.6M consensus. The leg is now…

AI-eats-BPO de-rating being unwound: the 2026-07-28 Q2 beat-and-raise put data-and-AI-led work at ~61% of revenue growing ~30% YoY and lifted the organic constant-currency guide to 13-14%. Stock gapped off a $30.53 close into the mid-$34s,…

Aug 6 flipped the frame: Q2 revenue $448.8M/+14.9% vs $415.0M consensus, adj EPS $0.35 vs $0.28, and the first FY guide raise of the cycle ($1.67–1.71B). Needham upgraded to Buy/$28, RBC to $24 — targets moved above spot for the first…

Small-cap oilfield-equipment operating-leverage re-rating: the 2026-07-30 Q2 beat ($1.16 adj EPS vs $0.56 est) plus an FY26 revenue guide lifted to $870–910M drove a 52-week high inside a week. The leg is accelerating, but the next company…

Growth re-acceleration narrative flipped live on the 2026-08-06 Q2 print: revenue +28.8% to $196.6M, FY2026 guide raised to $757.318M from $719.452M–$732.074M, buyback doubled to $200M. Unresolved is margin quality — 780bp of the 820bp…

Probe-card pick-and-shovel to the HBM4 test ramp; after a parabolic run to a fresh $160.27 ATH (2026-06-30) on Russell 1000 inclusion, the 2026-07-02 chip selloff cut FORM ~24% to ~$121. HBM inflection intact (record DRAM quarter, second…

Software-supply-chain-security plus AI-agent "trust layer" narrative keeps re-rating: the analyst cluster now leads price above $100 (UBS Buy $110 Jul 2, Truist Buy $105 Jul 9), confirming the continuation tell flagged in June.…

Security-led margin inflection: the 2026-08-05 Q2 print put adj EBITDA at $38.1M vs $8.9M YoY and lifted the FY26 adj EPS guide to $0.50-0.54 from $0.27-0.33 — and the stock fell ~10%. Narrative reads MATURING: three target raises to…

Legacy oilfield chemistry re-rating into a power/measurement business: Data Analytics hit 51% of gross profit in Q2 2026, the 2026-08-03 PREPA award adds ~$400M of 10-year expected backlog, and the 2026-08-04 guide went to $340–350M from…

Q2 landed early (2026-07-29) and resolved up: revenue $2.047B vs ~$1.89B consensus, product revenue +52% YoY, FY26 guide raised to $8.020–8.180B and EPS to $3.41–3.47. But twelve desks lifted targets on 2026-07-30 with zero rating…

Q2 (2026-07-29) beat and lifted the FY26 floor — adj EPS $0.23 vs $0.18, revenue $678.2M vs $647.5M, EBITDA guide to $205–220M — and four target raises to $22–26 followed. But the whole earnings week was given back by 7/31 ($19.17 vs…

Post-print re-rating: Q2 2026 revenue $411.6M (+27.6% YoY), gross margin 25.6% vs 23.9%, and a new $120M buyback carried GCT to a 52-week-high close of $53.25 on 2026-08-07 with RSI(14) 85.9. The leg is one event old and unbroken, but…

Q2 (7/30) resolved the earnings binary favourably: revenue $334.978M vs $314.226M consensus, FY26 guidance raised to $1.340–1.360B from $1.300–1.320B. But Guardant filed a shelf the same day, and the 7/31 target wave ($195–210) failed to…

Eli Lilly's up-to-$3.8B AtaiBeckley buy (2026-07-16) put a large-cap price on 5-MeO-DMT for depression; GHRS is now the last independent pure-play, with best-in-class inhaled GH001 Phase 2b data, that the sector is repricing as the next…

Product-led monetization pivot intact, but momentum has stalled: shares faded from $15.69 (7/10) to $14.85 (7/24) after Morgan Stanley's 2026-07-01 Overweight ($18 PT), heading into a binary Q2 print on 2026-08-06. EDGE ultra-premium tier…

FCC's 2-1 repeal of the 39% national TV ownership cap (2026-08-05/06) plus a Q2 beat-and-raise (revenue $839M vs $794.133M est; Q3 guided $935–965M vs $896.417M est, 2026-08-07) re-rated a 5.73x-levered broadcaster inside one week. Midterm…

Q2 (2026-08-06) beat its own guide — $227.4M revenue, GM 33.1% — and the Q3 guide ($243.3–252.4M, 8–10¢/ADS) cleared consensus ($235.3M, $0.05) by a wide margin. But the beat came from automotive Tcon (>50% of revenue), not the AI-glasses…

The August CMBS binary resolved most of the way toward the bulls — special servicer agreed extension terms per the 2026-08-05 call — and Q2 Core FFO $0.35 beat $0.26 on a raised $1.12–$1.20 FY guide. Yet the 2026-08-07 close of $14.36 is…

Second-order AI/power play: Herc rents the cranes and gensets that build data centers. Peer United Rentals raised FY26 guidance (2026-04-23), confirming an accelerating theme — but the stock sits +71% off its low and drifts into a binary…

The 2026-08-06 Q2 beat re-lit a squeeze the index deletion had just flushed: adjusted corporate EBITDA $81M cleared the top of a $50–80M guide, GAAP swung to +$64M, and the stock ran roughly 50% in two sessions amid 73.85%-of-float short…

Restatement discount unwinding on a CRO whose bookings stopped deteriorating: the investigation closed 2026-05-27 with 2023/2024 revenue overstated only 0.8%/1.1%, then two straight beats (Q1 06-23, Q2 07-29) with FY26 affirmed both times.…

Darovasertib approval trade: OptimUM-02 registrational win (HR 0.42, PFS 6.9 vs 3.1 mo, ASCO 2026-06-01) puts a first US uveal-melanoma NDA in flight under FDA RTOR, filing guided H2 2026. Fortress balance sheet (~$973M cash Q1 + $300M…

Q3 FY26 (2026-07-31) resolved the post-index-inclusion fade in the bulls' favour — revenue $1.243B (+40%), backlog $4.53B (+91% since FY25 close), Communications +51% — and the 2-for-1 split distributing 2026-08-21 is the only dated event…

Beat-and-raise on 2026-07-30 (rev $1.159B +9.4%, EPS $1.31, FY26 guide up to $4.60–4.64B / $5.30–5.40) drew nine target hikes to as high as $230 — and the stock still closed 2026-08-07 at $187.96, 8.4% below the $205.10 high made on the…

Premium-large-format flywheel narrative accelerated on the 2026-07-23 Q2 beat ($102.8M revenue vs $93.7M consensus, $0.43 adj EPS vs $0.28) and July's record $257M IMAX month; the story is now mainstream-covered, six sell-side targets set…

Memory-cycle re-rating in an AI costume just re-accelerated: June 2026 revenue +37.2% YoY and Q2 +28.7% YoY (both records since 2014, reported 2026-07-10) erase the May deceleration scare, and price bought back the ~17% fade to sit ~$68…

Post-derate re-rating accelerating after the 2026-08-04 Q2 print: adj EPS $4.37 vs $3.75 est, contract-value growth up 70bps sequentially, FY26 EPS guide raised to ≥$14.00, +$500M buyback added 2026-07-30 — but shares gapped 23.7% in one…

Analyst-migration re-rate's second leg (Morgan Stanley to Overweight, PT $400, 2026-07-13) has stalled — silent tape near 28x forward, empty calendar until the ~2026-08-19 Q3 FY26 print. The $290–300 breakout-shelf entry hasn't come;…

Gas-compression operator repriced as a behind-the-meter data-center power supplier; the 2026-07-08 Baker Hughes multi-year turbine agreement de-risks the equipment supply chain for the >2 GW buildout, but the re-rating is sell-side-mature…

Turnaround re-rating went live in July: KMX broke the $50–$53 shelf to close $57.33 on 2026-07-17 (+17.2% in five sessions) after a Q1 FY27 blowout (EPS $1.31 vs ~$0.95, revenue $8.01B +6.2%), CEO Keith Barr buying 9,400 shares at $53.005…

Rare-disease commercial re-rating: ARCALYST Q2 revenue $243.6M (+~55% YoY) beat $225.5M consensus and FY26 guidance jumped to $980–995M from $930–945M on 2026-07-28, triggering a target ladder to $90–107. The leg is now momentum with no…

TiO2 cyclical inflection printed 2026-08-05: Q2 EPS $0.13 vs -$0.04 consensus, sales $558.1M vs $502.3M, segment profit $41.0M vs $10.9M. The 10-Q shows inventory down to $498.3M from $549.3M QoQ, so the volume beat was partly…

Legacy dealer group re-rating on non-store earnings: Q2 (2026-07-29) adj EPS $10.03 vs $8.78 consensus was carried by Driveway Finance ($884M originations, $36.5M income) while same-store revenue fell 1.6%. Dividend +23%, $500M added to…

Sell-side catch-up fired: Barclays (2026-07-14, $9→$13) and KeyBanc (2026-07-13, $11→$13) both raised to $13 within 24 hours, and LFST printed a fresh 52-week high at $11.68. Behavioral-health margin inflection is now consensus rather than…

The 2026-08-03 binary resolved up: Q2 revenue $199.2M beat $185.85M est, adjusted EBITDA +31% to $32.5M, occupancy 91%, FY revenue guide lifted to $830–860M, Stifel to $37 (Aug 4). But the EBITDA guide stayed $130–140M on +64% YoY fuel…

Hormuz truce collapsed 2026-07-08 — Iran re-struck shipping and re-closed the Strait, re-firing VLGC rates to fresh 2026 highs (BLPG3 $220/ton, TCE $125k/day, week of Jul 10). This pure-play VLGC name re-accelerated off its $36 late-June…

YUTREPIA commercial ramp plus S&P SmallCap 600 inclusion and a SCOTUS-de-risked '327 overhang pushed LQDA to new highs near $80 — but the coiled asymmetry is spent: price now sits above the ~$69 consensus target with insiders selling into…

Cloud-transition completion plus an agentic-AI attach is re-rating a supply-chain software name: the 2026-07-28 Q2 beat carried RPO of $2.47B (+23% YoY) and a raise to every FY26 guidance line, followed by four target hikes into the…

Thesis has flipped from cyclical rollover to agentic-distribution re-rate: P&C revenue +31.1% YoY in Q1 (2026-04-29), the autoinsurance.net ChatGPT app live since 2026-04-02, and price at a 52-week high of $14.39 (2026-07-15) some 38%…

Biotech-funding-recovery narrative re-accelerating through the CRO channel: Q2 (2026-07-22) new business awards +28.2% YoY to $795.7M, book-to-bill 1.13x, and FY26 revenue AND EPS guides both raised. The buyable leg is a bookings…

Data-center power pivot is revenue-confirmed — record >$80M FY26 segment sales and an FY27 guide ($1.025–1.075B vs ~$952M Street) — but the post-print momentum leg has faded ~26% from the $20.38 high to ~$15. The re-rate is spent and the…

Platform inflection: Ryoncil delivered $115M first-year revenue above its $110-120M guide, and Mesoblast is stacking regulatory optionality — a modular BLA filed for rexlemestrocel-L in LVAD heart failure plus a fully-enrolled Phase 3…

The $400M Oberland royalty deal (2026-07-07) took dilution and runway risk off the table and spiked MGTX to a new 52-week high of $15.35 before a fade to ~$12.44 — a non-dilutive re-rate of a three-program AAV gene-therapy pipeline, but…

Rare-disease franchise ran to a $125 ATH on FOP data, then cooled ~9% into a confirmed 2026-07-30 Q2 print. Base compounds (Q1 sales +43% YoY, FY guide $660–680M) with FOP PDUFA 2026-09-26 and HDV Phase 3 topline 2H26 stacked ahead — but…

Carve-out re-rate re-firing: MMED closed $16.93 on 2026-07-17 (+6.61%, volume 26% above average, intraday $17.15), reclaiming the $17 handle for the first time since the June fade — on group confirmation from Abbott's 07-16 print and…

Q2 (2026-08-06) turned Manitowoc from a levered crane laggard into an earnings-inflection name: orders +56% to $709M, backlog above $1B for the first time, FY26 adj EPS guided to $0.80–1.20 vs $0.48 consensus. The leg being bought is…

AI/datacenter power-buildout supercycle lifting grid/electrical contractors; MYRG confirmed it with a record Q1 and a late-June breakout to fresh ATHs (~$487) above the $484.71 shelf. Theme ACCELERATING + cluster-confirmed, but the Q2…

Post-3M-integration cleanup finally printing: Q4 FY26 on 2026-07-30 beat both lines ($225.3M vs $212.4M est; $0.09 adj EPS vs $(0.07)), FY27 guided to $880–885M against $849.6M consensus, and the $160M Zoetis Genomics sale funds a sub-3x…

Agentic-AI trust-layer narrative still ACCELERATING with full sell-side capitulation — nine target raises in ~16 days into a $300–330 cluster — but the tape now sits ~13% above the reclaimed $256.79 ATH at ~36x sales with the ~2026-08-06…

Rett gene-therapy story materially de-risked: FDA Breakthrough Therapy (Feb 27), Embolden pivotal fully dosed (Jun 8, 25 pts), clean 1E15 safety, and a $125M raise at $30 funding past 2028. But the next hard binary — Embolden topline — is…

M&A read-through re-accelerating: AbbVie's $10.9B Apogee buyout (June 22, 2026) reframed NKTR as the next takeout-able Treg-IL-2 atopic-dermatitis asset, driving a ~25% run off the June low to ~$70. It's sympathy optionality, not fresh…

Private-flood insurtech disrupting the federal NFIP; the 2026-07-21 Q2 beat-and-raise (EPS $0.15 vs $0.14, FY guide lifted to $199M) refuted the deceleration fear and triggered a cluster of price-target hikes to $36–39. Narrative velocity…

Roche co-development deal (2026-07-21: $700M upfront, up to $2.3B, 60/40 cost-share) just gave Big Pharma validation to the bexobrutideg BTK-degrader franchise the sell-side re-rated in July, re-accelerating the narrative. But no dated…

Post-lockup repair leg is working: NTSK closed $14.87 on 2026-08-07 (+28.0% 3m) and cleared the ~$14 breakdown shelf while Gartner named it an SSE Leader for a fifth year (2026-08-04). Still ~3x EV/S on 29% ARR growth and -42.3% from the…

Spintronics micro-cap re-rated ~52% in one session on a step-change quarter — revenue +81% to $11.034M, gross margin 81.3%, EPS $1.32 (2026-07-22) — after FY2026 grew just 1.76%. The leg being bought is a structural inflection in…

Falling knife has based and turned: after a -34% unwind from the $163 high to a ~$107 June base, a fresh cluster (Truist initiate Buy $140 07-14, Guggenheim upgrade Buy 07-15) plus a 07-15 surge is re-rating the M&A-drift story. The…

Digital-chronic-care re-rating accelerating: the GLP-1 wave expands rather than shrinks Omada's TAM as the scaled behavior-change layer on obesity drugs. Q1 beat-and-raise (rev +42% to $78M, FY guide lifted to $322–330M) plus a $30…

BRUKINSA-driven oncology compounder: sell-side racing to catch up — six PT raises/upgrades Jul 1–23, avg PT ~$415 vs ~$326 spot — as the drug takes global BTK leadership and BeOne turns GAAP-profitable. The 2026-08-05 Q2 print is the…

Legacy residential VoIP re-rating into an SMB cloud-comms roll-up: Q1 FY27 (2026-05-26) revenue $81.1M +25% YoY, FY27 guide lifted to $326.0–328.5M on ~31% business-segment growth. Price sits 0.8% under the $22.14 52-week high going into…

Margin-repair turnaround at a non-prime installment lender: the 2026-08-05 Q2 print beat at $0.42 adj EPS vs $0.33, FY adj EBITDA guide was raised to $160–175M and the FY charge-off band tightened to 11.7% ±30bp. Stock closed 2026-08-07 at…

Supply overhang cleared: the 2026-07-01 Fairmount $300M block at $84.43 was absorbed and price closed $92.70 on 07-17 (+11.6%), 5% off the 52-week high, with 19.85% short interest still rising. Long-acting I&I re-rated by the $10.9B…

Setup inverted since the June breakdown. OXM reclaimed its 200-day ($39.11) and 50-day ($39.94) off the $35.83 low, the CEO bought 2,500 shares at $36.90 on 2026-06-12, and ~$25M of filed IEEPA tariff-refund claims — 4% of market cap,…

Pharma copay-affordability leg compounding: Q1 (2026-05-12) patient-affordability revenue +82% YoY to $15.7M, pharma overtook plasma as largest segment. Price broke to a new 52-week high $9.30 and held $8.55 (2026-07-17), +89% in six…

Construction-software margin inflection plus a fresh AI/reality-capture leg: the 2026-07-29 Q2 beat ($375.2M vs $365.8M), first GAAP operating profit, an initiated FY27 25% margin target and an $845M DroneDeploy deal funded by $825M of…

Post-print re-rating leg: the 2026-08-04 Q4 FY26 beat ($1.84 adj. EPS vs $1.61 est.) triggered five price-target raises in 48 hours and a $150.42 close on 2026-08-07, +35.5% over three months. The buy is multiple recovery in mid-cap HCM…

The read has flipped from value trap to ownership story. Price reclaimed the 200-DMA (~$10.30 on 2026-07-17, +13% in three weeks), Truist lifted its PT to $11 on 2026-07-09, and the 2026-07-14 addition of Alex Shootman — who sold Workfront…

Q3 (July 7) broke the model wide open: revenue $478.7M vs $405.5M consensus (+48% YoY), EPS $0.84 vs $0.54, FY26 growth guide lifted 12%→22% and FY27 pre-guided ~30%. The stock then round-tripped from $89.86 to ~$60 on the $750M…

iCasino-led digital turnaround gliding toward Q4-2026 interactive profitability as the regional-gaming cycle re-rates; the June–July sell-side upgrade cluster has now largely fired, leaving an extended name near 52-week highs into the…

Nuclear-cleanup inflection accelerating: Hanford vit-plant hot commissioning plus DOE grouting awards (200W ~$216M/yr, 200E ~$75M/yr) repricing a ~$62M-revenue cleanup contractor as a multi-bagger. Shares broke to a 52-week high (+13.6%…

PAPZIMEOS launch-ramp durability is the binary — the first FDA-approved RRP therapy printed $21.6M net product revenue in Q1 2026, and the now-confirmed Aug 4 Q2 print (announced Jul 21) grades whether the ramp compounds sequentially or…

Fertility-benefits re-rate broke out rather than stalled: PGNY cleared the $28.75 shelf and printed a new 52-wk high $33.06, trading ~$31.9–32.5 after KeyBanc lifted its target to $35 on 7/13. Price now sits above the $30.73 consensus, so…

Specialty-P&C compounder re-rating: three Overweight/Outperform PT raises to $165–167 in 12 days (KBW 07-08, Piper 07-15, JPM 07-20) drove a breakout to new highs, +25% in a month on 42% GWP growth. Narrative re-accelerating and sell-side…

Geopolitical crude bid re-fired after the 2026-07-08 US strikes and Hormuz blockade — WTI back to ~$80 from $68.86, PNRG +8.9% MTD to $186.51 and above the 200-day. Structurally better than June: GCX in-service flipped Waha gas positive,…

Reciprocal-pivot re-rate has largely printed: $9.26 (6/5) to $15.98, now consolidating at $13.68 after KBW's 7/13 valuation downgrade that still raised its target to $16.25. Narrative intact but maturing; the 2026-08-04 Q2 print is the…

Disciplined software roll-up ("Total Growth Strategy") re-rated by a fresh catalyst cluster: Q2 beat + FY guide raise (2026-06-30) and the $400M Domo buy (2026-07-22). Special-situations theme active, but a MATURING low-beta compounder —…

Monopoly wildfire retardant (PHOS-CHEK) into a season at national Preparedness Level 5 — 3.85M acres burned YTD (NIFC, 7/18), ~157% of the 10-yr average. JPM initiated Overweight $50 on 7/9, lifting the 4-analyst average target to $45.…

De-risked dual-royalty story accelerating into a binary: icotrokinra (oral IL-23, J&J) already approved and paying 6–10% royalties; rusfertide (PV, Takeda) into a Q3 2026 PDUFA. Stock at a fresh ATH ($143.29, Jul 20) as the PV theme runs —…

First-approved-therapy-for-microcystic-lymphatic-malformations story is accelerating and de-risked — SELVA hit its endpoint, FDA granted rolling NDA review, first module filed June 29. But the real binary (NDA completion H2 2026, approval…

Live takeover: Stripe/Advent's $60.50 bid (>$53B) sent PYPL +17.2% to $56.56; board called it inadequate (Reuters 2026-07-17), leaving a ~7% gross spread plus bump optionality against a ~17% break to the ~$47 pre-approach shelf. Q2 FY26…

Left-for-dead vuln-management de-rate re-rating on a 2nd-order AI-demand reframe — AI code-gen and attackers expand the vulnerability surface, feeding demand to the installed base. A cohort (JPM, Scotiabank, Cowen, Truist) has now…

Auto-insurance carrier ad-spend recovery still reaccelerating: revenue snapped from +2% YoY (Dec quarter) to +28% ($346.1M, fiscal Q3), and the Q4 guide implies ≥34% revenue / ≥67% EBITDA growth. But the Aug 6 FY2027 guide is a binary the…

De-rated digital-banking SaaS re-rating on a margin inflection: 2026-07-29 beat-and-raise took FY26 to $881–886M, adj. EBITDA margin to 28.6% from 23.5%, cleared the converts and added $350M to the buyback. AI products (Q2 Assistant, Q2…

RAPP broke to all-time highs at $42.62 (2026-07-17, +6.2%) on zero company news — the move is pure sell-side re-rating (BTIG reiterated Buy/$65 on 7/16, consensus PT $56.64, 12 desks Strong Buy) with Phase 3 FOCUS now enrolling globally.…

Cross-border remittance profitability inflection is accelerating: Q1 2026 (May 6) net income +332% on revenue +25% and Adjusted EBITDA +74%, with FY guide raised. Clustered PT hikes to $30 (Goldman 06-29, Citizens 07-12) confirm sell-side…

Post-binary re-rating extended by an analyst-coverage land grab: JP Morgan initiated Overweight $28 (2026-07-08) and Canaccord Buy $29 (2026-07-16) on top of the June upgrade wave, carrying RLAY to a new 52-week high of $20.19 (~450% TTM).…

Corrected cash math changes the read: the $50.0M Candid break fee received 2026-05-04 landed after the 3/31 balance sheet, so ~$97M gross cash sits against 5.30M shares (~$18.3/sh) versus a $16.42 quote. Buyer gets the cash distribution…

Merger arb that finally got a date. DOJ granted HSR early termination 2026-07-13 and both special meetings are set for 2026-08-14, removing the regulatory leg. RMAX $11.10 vs ~$11.86 blended (5.150 REAX at $2.21 plus the prorated $13.80…

The takeout fight re-fired: Forager returned 2026-06-29 with $5.25 cash — 9% above the $4.80 the board killed in May — and was rejected again 2026-07-13, the same day the board seated a Parthenon-affiliated director under a cooperation…

Deleveraging turnaround repricing: ~$96M / 116-unit refranchising cuts net debt ~$147M→~$51M, removing the going-concern tail that pinned RRGB near $2.46. Tape +38.7% since the ~2026-05-20 Q1 print, into the low-$7s near the $7.89 high.…

The pre-registered re-rate tell fired: Scotiabank flipped to Sector Outperform on 2026-07-06, lifting its target to $23.50 from $16 — the second bank pivot after BofA. Price has run $15.91 (06-26) to $19.57 (07-17), reclaiming the ~$18…

Three-engine re-acceleration — Shopee GMV +30%, Monee loan book +71%, Garena's best quarter in 5 years — drove a Q1 beat (2026-05-12) and a +19% one-month recovery off the $77 low. Fundamentally accelerating, but the stock is short-term…

Four escalating take-private proposals in July 2026 — Radoff-JEC at $2.55 cash + CVR, Chair/CEO at $2.45 + two CVRs — against ~$220M of Q1-end cash and ~55M shares out. The Special Committee opened its mandate to "other alternatives" on…

Pure-play Capesize cycle: record Q2 on 2026-07-30 (adj EPS $1.32 vs $0.67 est, revenue $55.7M) landed with the Baltic Dry Index at a two-month high on 2026-08-07, yet the stock closed $16.86, 7.2% under its $18.17 high. Only ~71% of Q3…

Menin-inhibitor commercial ramp accelerating: Revuforj + Niktimvo franchise cleared $100M/quarter with revenue +224% YoY, and the leg being bought is frontline AML label expansion (~10x TAM). Stock coils below 52-week-high resistance…

De-rating-repair leg: Q2 (2026-07-30) beat on adjusted EPS $1.27 vs $1.09 with EBITDA +19% on 6% revenue growth, while the FY26 revenue band was cut on the 2026-06-30 3P divestiture. Price reclaimed the ~$70 200-day, but the fresh Morgan…

Data-center cooling fundamentals still accelerating — HVAC backlog $755.3M, +70% DC growth guide, Neptronic bolt-on 2026-07-23 — but price round-tripped the June breakout back to the ~$210 shelf with a binary Q2 print on 2026-07-30.…

Post-crackdown rebuild is compounding: Q1 FY2027 (2026-07-30) put revenue +31.9% YoY at $758.4M, gross margin 57.8% and operating income $137.2M vs $14.3M a year earlier, with S&M down 5%. The catch — $405.2M of the $408.0M net income was…

Legacy open-web ad network repricing as a toll booth on AI answer surfaces: the 2026-06-16 DeeperDive ad-network launch (35% take rate, open to third-party LLMs/agents) plus the 2026-07-01 Wikitree win drove a breakout to 52-week highs…

The "agentic AI kills seat-based software" de-rating just reversed: Q4 FY26 (2026-08-06) put cloud +31% and $6,606M subscription ARR behind the Rovo/MCP agent story, and the stock gapped 30%+ on 2026-08-07 to close $149.07. The…

Legacy vuln-scanner re-rated as an AI beneficiary: Hexa AI GA on Claude at a 60% tier premium, OpenAI Daybreak (2026-06-22), FedRAMP High/IL5 (2026-06-29), and four target raises in two weeks including Scotiabank's $26→$50 upgrade. Price…

Single-asset cardio micro-cap re-rating on a positive Phase 3 LEVEL topline (oral levosimendan) in PH-HFpEF, an indication with no approved therapy; the analyst cluster is now five desks deep after Evercore initiated Outperform $39 on…

Profitable anti-CD20 franchise (BRIUMVI) repricing on a credible MG second act; June's Phase 1 print and second FY2026 guide raise (~$925M global) are in the tape, and HC Wainwright's July 13 lift to a $77 target reloads the narrative into…

Hospital margin-expansion narrative re-rated on the 2026-07-24 Q2 beat and $295M FY26 adjusted-EBITDA guidance raise (+17.3% that session), with nine target hikes inside ten days carrying price to a 52wk high of $262.13. The leg is intact…

Second breakout leg confirmed: TRVI cleared the June $18.17 all-time high and printed $20.22 on a +9.85% July 17 session (8.3M shares, $19.07 close), lifting the tape ~+45% in six weeks on Phase 3 launch mechanics and institutional…

Legacy CPaaS repricing as voice/agentic-AI engagement infrastructure; sell-side re-clustered higher into the print — Cowen $245, Mizuho $240, Citizens $250 (2026-07-17/20) — but the 2026-07-30 Q2 report is now the binary deciding whether…

Synthetic-DNA-as-AI-input narrative went vertical: the failed $70 breakout reclaimed and ran to a $105.47 high, +200%+ YTD with 85% of it since the 2026-05-21 analyst day. Targets now $102-$120 but price sits above the $85.50 consensus and…

Vector AI ad-engine turnaround still re-rating — Wedbush lifted its target to $36 on 2026-07-22, extending the analyst cluster past the late-June "re-rating done" call. Strategic Grow guided +50-52% YoY ($302-306M), GAAP breakeven targeted…

Brazilian fuel-distribution margin re-rate (tax-evasion crackdown) plus a live Ipiranga sale process (~R$25-30B; TotalEnergies/Aramco/J&F, BTG advising) is the leg; Q1 net income +151% YoY, sell-side confirming late (B of A upgrade…

Dead-money value-trap read is inverting: UHAL broke to new 52-week highs (~$72, +15.9% in a month) as self-storage same-store re-accelerated to +7-8% (vs flat national tape) and a first $350M buyback signaled a capital-return shift.…

ZUSDURI launch ramp still accelerating and the sell-side is now chasing it — Oppenheimer to $50 (7/16), Guggenheim to $42 (7/21) — as price prints fresh 52-week highs near $41. The 2026-08-06 Q2 report is the binary tell on whether the…

July de-escalation trade is dead: Trump says Iran "not ready" to deal (07-24), Houthis struck two Saudi tankers (07-23), US hit an LPG tanker, and WTI cleared $100. USO is long a freshly re-arming, multi-front Gulf war premium —…

Sell-side is now chasing a move it missed: VCYT broke to a 52-wk high $60.91 (closed $59.13 on 2026-07-17, +124% YoY) as Piper initiated Overweight $66 (07-15) and Canaccord lifted a Hold PT $42→$60. Fundamentals still accelerating (Q1 rev…

European-gas-priced Canadian producer: the 2026-07-29 Q2 beat raised FY26 guidance to 121–123 Mboe/d and widened the payout framework to 40–60% of excess FCF, yet the 2026-08-07 close of $10.86 sits 24.2% under the $14.32 52-week high. The…

LNG-export narrative re-accelerating on Europe's winter gas scramble plus a Middle East risk premium; VG ran +23% off the $12 mid-July shelf to $14.31 as Plaquemines ramps and CP2 advances. The 2026-08-11 pre-market Q2 print is the binary…

Refiner crack spreads at a record ~$70/bbl 3-2-1 as a Hormuz/Iran supply shock idles ~10% of global refining; VLO is the pure-play margin leverage and the fundamental leg is accelerating. But sell-side (6 PT raises in 11 days) and CNBC…

Post-print air pocket in a live special situation: Q2 (2026-07-28) beat and lifted FY26 revenue to $735–739M, ~10 targets moved to $45–58, and the stock still closed 2026-08-07 at $43.52 — below every one of them, RSI 38.3. The 2026-06-23…

The dormant-tape problem flagged in July resolved: Q2 (2026-08-06) put net product revenue at $25.1M vs $23.093M consensus, the Oberland royalty deal funds runway into H2 2027 without equity, and the vague "H2 2026" VS-7375 readout is now…

Hated fuel-card/fintech inflecting: the 2026-07-22 Q2 beat (Adj EPS $5.35 vs $5.05) and FY26 guide raise to $19.68-$20.08 discredit the EV-kills-fuel-cards and rate-cut-kills-float bear case; PTs jumped to $200-210 (Mizuho/KBW, 7/24).…

International wellhead capex narrative accelerating after the 2026-07-29 Q2 beat (revenue $449.5M vs $399.3M est., adj. EPS $0.93 vs $0.62) plus >$130M of post-quarter international purchase orders. Tension: price closed $67.90 on…

Base44 margin inversion is the live leg: Q2 2026 (2026-08-04) printed revenue $563.1M +15% and guided Base44 to ~60% non-GAAP gross margin in 2H from near-zero, into a float cut 29.7% at $92.00 in April and a ~26%-short base.…

Produced-water midstream re-rate is now being underwritten rather than discovered: shares hit a 52-week high $20.48 (2026-07-17 close $20.33, +73.6% YTD) as consensus PT walked from ~$17.30 to ~$21.83 and Russell Growth-Defensive inclusion…

Tariff-margin-recovery turnaround now getting sell-side confirmation: Goldman upgraded to Buy/$63 on 2026-07-20 (vs Canaccord's $45 Hold a month earlier), pushing YETI through the $51.89 multi-year high. The leg still hinges on the…

First-in-disease B-cell modulator: obexelimab BLA (IgG4-RD, 56% flare cut, HR 0.44) hit the FDA 2026-05-28, and the ~60-day filing determination — acceptance plus a possible Priority Review grant — is due within days, a fresh near-term…

Palantir Foundry re-platforming now has a management clock — phase one guided complete within 30–40 days of the 2026-07-06 Citi event, landing on the ~2026-08-04 Q2 print. Price reclaimed the $21 shelf that capped the June recovery (+14%…